Tumor evolution in non-small-cell lung cancer
نویسندگان
چکیده
منابع مشابه
Sentinel Node Mapping in Non-small Cell Lung Cancer Using an Intraoperative Radiotracer Technique
Objective(s): Lymph node metastases are the most significant prognostic factor in localized non-small cell lung cancer (NSCLC). Identification of the first nodal drainage site (sentinel node) may improve detection of metastatic nodes. Extended surgeries, such as lobectomy or pneumonectomy with lymph node dissection, are among the therapeutic options of higher acceptab...
متن کاملClinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran
Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...
متن کاملThe Evolution of Therapies in Non-Small Cell Lung Cancer
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver mutations has led to new ways in classifying NSCLC as well as offered novel therapeutic targets for anticancer therapy. Targets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gen...
متن کاملTumor immunity landscape in non-small cell lung cancer
Even with the great advances in immunotherapy in recent years, the response rate to immune checkpoint inhibitor therapy for non-small cell lung cancer is only about 20%. We aimed to identify new features that would better predict which patients can benefit from an immune checkpoint blocker. This study is based on the publicly available gene expression data from The Cancer Genome Atlas lung canc...
متن کاملMolecular genetic tumor markers in non-small cell lung cancer.
Not only serum tumor markers, such as carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and carbohydrate antigen (CA) 125, but also serum growth factors have been examined to evaluate tumor stages and to predict the recurrence and metastasis in patients with non-small cell lung cancer (NSCLC) (1-5). In recent years, the analysis of the genome and proteome has advanced remark...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: ESMO Open
سال: 2018
ISSN: 2059-7029
DOI: 10.1136/esmoopen-2018-000436